Patent · US Active

Antagonistic anti-hTNFSF13b human antibodies

US7728109B2 · kind B2 · utility

7Cited by
3References
3Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 7, 2007
Grant dateJun 1, 2010
Priority date—
Expiry dateMar 12, 2028

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for TNFSF13b dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.